CN103288935B - 多肽 - Google Patents

多肽 Download PDF

Info

Publication number
CN103288935B
CN103288935B CN201310114471.0A CN201310114471A CN103288935B CN 103288935 B CN103288935 B CN 103288935B CN 201310114471 A CN201310114471 A CN 201310114471A CN 103288935 B CN103288935 B CN 103288935B
Authority
CN
China
Prior art keywords
egfr
binding
polypeptide
amino acid
binding peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310114471.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103288935A (zh
Inventor
F·尼尔森
T·埃里克松
A·荣森
S·斯托尔
M·弗里德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of CN103288935A publication Critical patent/CN103288935A/zh
Application granted granted Critical
Publication of CN103288935B publication Critical patent/CN103288935B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201310114471.0A 2005-12-05 2006-12-05 多肽 Expired - Fee Related CN103288935B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0524788.7A GB0524788D0 (en) 2005-12-05 2005-12-05 Polypeptides
GB0524788.7 2005-12-05
CNA2006800523510A CN101336250A (zh) 2005-12-05 2006-12-05 多肽

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800523510A Division CN101336250A (zh) 2005-12-05 2006-12-05 多肽

Publications (2)

Publication Number Publication Date
CN103288935A CN103288935A (zh) 2013-09-11
CN103288935B true CN103288935B (zh) 2017-11-17

Family

ID=35686099

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310114471.0A Expired - Fee Related CN103288935B (zh) 2005-12-05 2006-12-05 多肽
CNA2006800523510A Pending CN101336250A (zh) 2005-12-05 2006-12-05 多肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006800523510A Pending CN101336250A (zh) 2005-12-05 2006-12-05 多肽

Country Status (9)

Country Link
US (3) US8247375B2 (https=)
EP (2) EP2431383B1 (https=)
JP (2) JP5898826B2 (https=)
CN (2) CN103288935B (https=)
CA (1) CA2631430C (https=)
DK (1) DK2431383T3 (https=)
ES (1) ES2599996T3 (https=)
GB (1) GB0524788D0 (https=)
WO (1) WO2007065635A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
KR101658247B1 (ko) * 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US9238810B2 (en) 2008-06-05 2016-01-19 Affibody Ab Polypeptide
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
EP2728000B1 (en) * 2011-06-03 2018-12-05 National Institute of Advanced Industrial Science And Technology Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
JP6440618B2 (ja) 2012-10-05 2018-12-19 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
EP3245224B1 (en) 2015-01-12 2020-07-15 Affibody AB Il-17a-binding polypeptides
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
US10521754B2 (en) * 2016-03-08 2019-12-31 Auctane, LLC Concatenated shipping documentation processing spawning intelligent generation subprocesses
CN111925425B (zh) * 2020-08-12 2023-03-10 天津科技大学 甲胎蛋白特异性结合多肽及应用
JP2025507294A (ja) * 2022-02-04 2025-03-18 ザイトックス セラピューティクス アクチボラゲット Ｅｇｆｒ結合ドメインとマスキングドメインとを含む融合タンパク質
TW202416938A (zh) 2022-08-10 2024-05-01 日商興和股份有限公司 親和體微胞(affibody micelle)藥物複合體
EP4644417A4 (en) * 2022-12-30 2026-02-11 Abclon Inc AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE
CN117106035B (zh) * 2023-10-25 2024-04-23 烟台药物研究所 一种肿瘤靶向多肽、多肽偶联药物及制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003156A1 (en) * 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
SE0301936D0 (sv) 2003-06-30 2003-06-30 Affibody Ab New polypeptide
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JPWO2005095419A1 (ja) 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
JPWO2005100983A1 (ja) 2004-04-16 2008-03-06 英俊 岡部 悪性腫瘍の検査方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003156A1 (en) * 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2

Also Published As

Publication number Publication date
US20140178301A1 (en) 2014-06-26
US8598113B2 (en) 2013-12-03
US20090016957A1 (en) 2009-01-15
GB0524788D0 (en) 2006-01-11
JP2009519013A (ja) 2009-05-14
EP1973934B1 (en) 2014-11-05
JP5898826B2 (ja) 2016-04-06
EP1973934A1 (en) 2008-10-01
CA2631430C (en) 2017-03-07
US8247375B2 (en) 2012-08-21
CN103288935A (zh) 2013-09-11
ES2599996T3 (es) 2017-02-06
DK2431383T3 (en) 2017-01-09
EP2431383B1 (en) 2016-09-28
US9107965B2 (en) 2015-08-18
WO2007065635A1 (en) 2007-06-14
EP2431383A1 (en) 2012-03-21
CA2631430A1 (en) 2007-06-14
CN101336250A (zh) 2008-12-31
JP2014087361A (ja) 2014-05-15
US20130005653A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
CN103288935B (zh) 多肽
Friedman et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor
Friedman et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule
AU2004253835B2 (en) Polypeptides having binding affinity for HER2
Malmberg et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts
EP2904013B1 (en) Her3 binding polypeptides
US20250215093A1 (en) Fusion protein comprising an egfr-binding domain and a masking domain
EP4424703A1 (en) Polypeptides for transferrin receptor-mediated transcytosis
HK1186197B (zh) 多肽
HK1186197A (en) Polypeptides
HK1125657A (zh) 多肽
CN114829388A (zh) 抗her2多肽衍生物作为新的诊断分子探针
CN115244073B (zh) 抗her2多肽衍生物作为新的诊断分子探针
Quan et al. Imaging tumor endothelial marker 8 using an 18F-labeled peptide
HK1207657B (en) Her3 binding polypeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1186197

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1186197

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171117